{"entity":{"id":"nct07722767","kind":"trial","name":"A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients","aka":[],"tldr":"A phase 1 trial of CLN-049 run by Cullinan Therapeutics Inc., not yet recruiting.","summary":"A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients is a phase 1 interventional study registered as NCT07722767 by Cullinan Therapeutics Inc., with 90 participants planned, started 2026-10-15. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CLN-049, Azacitidine and Venetoclax.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07722767","url":"https://clinicaltrials.gov/study/NCT07722767"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cln-049"],"companies":["cullinan-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07722767","phase":"1","setting":"A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia","sponsor":"Cullinan Therapeutics Inc.","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07722767/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"cln-049","kind":"drug","name":"CLN-049","route":"/drugs/cln-049/"}],"company":[{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/"}]}}